Peer-Reviewed Publications

      Inflammatory bowel disease-associated changes in the gut: Focus on Kazan patients

      Lo Sasso, G.; Khachatryan, L.; Kondylis, A.; Battey, J. N. D.; Sierro, N.; Danilova, N. A.; Grigoryeva, T. V.; Markelova, M. I.; Khusnutdinova, D. R.; Laikov, A. V.; Salafutdinov, I. I.; Romanova, Y. D.; Siniagina, M. N.; Vasiliev, I. Y.; Boulygina, E. A.; Solovyeva, V. V.; Garanina, E. E.; Kitaeva, K. V.; Ivanov, K. Y.; Chulpanova, D. S.; Kletenkov, K. S.; Valeeva, A. R.; Odintsova, A. K.; Ardatskaya, M. D.; Abdulkhakov, R. A.; Ivanov, N. V.; Peitsch, M. C.; Hoeng, J.; Abdulkhakov, S. R.
      Published
      Aug 7, 2020
      DOI
      10.1093/ibd/izaa188
      PMID
      32766755
      Link to publication
      Topic
      Summary

      Background: Several studies have highlighted the role of host–microbiome interactions in the pathogenesis of inflammatory bowel disease (IBD), resulting in an increasing amount of data mainly focusing on Western patients. Because of the increasing prevalence of IBD in newly industrialized countries such as those in Asia, the Middle East, and South America, there is mounting interest in elucidating the gut microbiota of these populations. We present a comprehensive analysis of several IBD-related biomarkers and gut microbiota profiles and functions of a unique population of patients with IBD and healthy patients from Kazan (Republic of Tatarstan, Russia). Methods: Blood and fecal IBD biomarkers, serum cytokines, and fecal short-chain fatty acid (SCFA) content were profiled. Finally, fecal microbiota composition was analyzed by 16S and whole-genome shotgun sequencing. Results: Fecal microbiota whole-genome sequencing confirmed the presence of classic IBD dysbiotic features at the phylum level, with increased abundance of Proteobacteria, Actinobacteria, and Fusobacteria and decreased abundance of Firmicutes, Bacteroidetes, and Verrucomicrobia. At the genus level, the abundance of both fermentative (SCFA-producing and hydrogen (H2)-releasing) and hydrogenotrophic (H2-consuming) microbes was affected in patients with IBD. This imbalance was confirmed by the decreased abundance of SCFA species in the feces of patients with IBD and the change in anaerobic index, which mirrors the redox status of the intestine. Conclusions: Our analyses highlighted how IBD-related dysbiotic microbiota—which are generally mainly linked to SCFA imbalance—may affect other important metabolic pathways, such as H2 metabolism, that are critical for host physiology and disease development.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.